TREE NEWS update: AriBio presented results from the global Phase III POLARIS-AD trial of its oral drug candidate AR1001 at the CTAD conference, showing a 31% reduction in disease progression in the monotherapy population. The study enrolled 1,535 participants with early Alzheimer’s disease.
AriBio’s AR1001 Slows Alzheimer’s Progression 31% in Phase III Trial
A 31% slowing of progression in a monotherapy population is a meaningful signal in a field where disease-modifying wins have been scarce, and the oral route gives AR1001 a practical edge over infused alternatives. The result matters most for early-stage Alzheimer's patients and the developers betting on small-molecule approaches. The open question is whether the monotherapy subgroup finding holds up under the scrutiny that typically follows conference presentations, and how regulators weigh a single Phase III readout.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.